Dogma Biotech uses an AI platform to engineer minimalist glycans for protein therapies, enhancing efficacy and reducing manufacturing costs by up to 5X. This approach unlocks novel glycomics space, enabling the development of more potent and cost-effective biotherapeutics.
Funding
$100K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional protein therapies often face limitations due to complex glycosylation processes, leading to high manufacturing costs and suboptimal therapeutic efficacy. This complexity restricts the development of advanced biotherapeutics that could otherwise offer significant clinical benefits.
Solution
Dogma Biotech leverages an AI-driven platform to engineer minimalist glycans, unlocking novel glycomics space for biotherapeutic development. This approach allows for the creation of protein therapies with enhanced efficacy that meet or surpass natural glycosylation performance, as validated in preclinical studies. By simplifying post-translational modifications, the platform significantly reduces protein manufacturing costs by up to 5X while simultaneously improving therapeutic outcomes. This enables the development of therapies previously constrained by intricate modifications, offering a more cost-effective and potent solution.
Target Audience
The primary target audience includes biopharmaceutical companies and drug developers seeking to optimize protein therapy efficacy and reduce manufacturing overhead through advanced glyco-engineering.
Features
- AI-driven glycan engineering platform for de novo glycan design
- Minimalist glycan structures that mimic or exceed natural glycosylation efficacy
- Streamlined post-translational modification process to boost host-cell productivity
- Reduced protein manufacturing costs by up to 5X compared to conventional methods
- Preclinical validation demonstrating matched or superior therapeutic efficacy against commercial benchmarks
- Proprietary algorithms for exploring and exploiting previously inaccessible glycomics space